There has been no shortage of LP allocations to the growth equity asset class over the last decade. The attractiveness of growth equity’s risk-return profile - occupying the space between VC and PE buyouts - and its exposure...more
Although COVID-19 is rightfully viewed primarily as a public health and humanitarian issue, it is worth considering the potential impacts of the virus on M&A activity as this dynamic situation unfolds. We are seeing the issue...more
3/5/2020
/ Acquisitions ,
Best Practices ,
Business Continuity Plans ,
China ,
Contract Negotiations ,
Contract Terms ,
Coronavirus/COVID-19 ,
Debt Financing ,
Due Diligence ,
Force Majeure Clause ,
Infectious Diseases ,
Material Adverse Change Clauses (MACs) ,
Mergers ,
Private Equity Funds ,
Public Health ,
Regulatory Agencies ,
Representations and Warranties ,
Risk Management ,
Termination Fees ,
Tolling Provisions